Accuracy of amplitude-based respiratory gating for PET/CT in irregular respirations

[1] Lardinois D(2003)Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography N Engl J Med. 348 2500-2507

[2] Weder W(2001)The utility of 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification J Nucl Med. 42 1605-1613

[3] Hany TF(2004)Role of FDG-PET in the diagnosis and management of lung cancer Expert Rev Anticancer Ther. 4 561-567

[4] Kamel EM(2004)Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review Lancet Oncol. 5 531-540

[5] Korom S(1999)Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT Radiology. 213 530-536

[6] Seifert B(2006)Is standardised 18F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer Eur J Nucl Med Mol Imaging. 33 263-269

[7] Hicks RJ(2009)Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan Radiother Oncol. 91 386-392

[8] Kalff V(2007)Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients Radiother Oncol. 82 145-152

[9] MacManus MP(2008)Factors affecting quantification in PET/CT imaging Current Med Imaging Rev. 4 34-45

[10] Ware RE(2002)PET–CT image co-registration in the thorax: influence of respiration Eur J Nucl Med. 29 351-360

[1] Lardinois D(2003)Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography N Engl J Med. 348 2500-2507

[2] Weder W(2001)The utility of 18F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification J Nucl Med. 42 1605-1613

[3] Hany TF(2004)Role of FDG-PET in the diagnosis and management of lung cancer Expert Rev Anticancer Ther. 4 561-567

[4] Kamel EM(2004)Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review Lancet Oncol. 5 531-540

[5] Korom S(1999)Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT Radiology. 213 530-536

[6] Seifert B(2006)Is standardised 18F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer Eur J Nucl Med Mol Imaging. 33 263-269

[7] Hicks RJ(2009)Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan Radiother Oncol. 91 386-392

[8] Kalff V(2007)Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients Radiother Oncol. 82 145-152

[9] MacManus MP(2008)Factors affecting quantification in PET/CT imaging Current Med Imaging Rev. 4 34-45

[10] Ware RE(2002)PET–CT image co-registration in the thorax: influence of respiration Eur J Nucl Med. 29 351-360